Measuring Friedreich ataxia: complementary features of examination and performance measures.
about
Antioxidants and other pharmacological treatments for Friedreich ataxiaDevelopment of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxiaImpaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.Common data elements for clinical research in Friedreich's ataxia.Assessing function and endurance in adults with spinal and bulbar muscular atrophy: validity of the adult myopathy assessment tool.Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.Ophthalmic features of Friedreich ataxia.Frataxin levels in peripheral tissue in Friedreich ataxia.Antioxidant use in Friedreich ataxiaCardiac transplantation in Friedreich ataxiaFriedreich ataxia clinical outcome measures: natural history evaluation in 410 participantsFunctional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia.Progression of Friedreich ataxia: quantitative characterization over 5 yearsWhite matter changes in patients with friedreich ataxia after treatment with erythropoietin.Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials.A review of Friedreich ataxia clinical trial results.Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.Systematic review of the psychometric properties of balance measures for cerebellar ataxia.Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.Pharmacological therapeutics in Friedreich ataxia: the present state.Impact of diabetes in the Friedreich ataxia clinical outcome measures study.Cognition in late-onset Friedreich ataxia.Loss of intrinsic organization of cerebellar networks in spinocerebellar ataxia type 1: correlates with disease severity and duration.Effects of genetic severity on glucose homeostasis in Friedreich ataxiaMortality in Friedreich's Ataxia.Cerebellar atrophy is infrequently [corrected] associated with non-paraneoplastic sensory neuronopathy.Analysis of the visual system in Friedreich ataxia.Measuring disease progression in giant axonal neuropathy: implications for clinical trial design.Mortality in Friedreich's Ataxia.Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.A longitudinal study of the SF-36 version 2 in Friedreich ataxia.Cerebello-cerebral connectivity deficits in Friedreich ataxia.Restless legs syndrome in Friedreich ataxia: a polysomnographic study.Superior cerebellar peduncle atrophy in Friedreich's ataxia correlates with disease symptoms.Open-label pilot study of interferon gamma-1b in Friedreich ataxia.How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?Friedreich ataxia: executive control is related to disease onset and GAA repeat length.Assessment of speech in early-onset ataxia: a pilot study.Clinical measures of dysarthria in Friedreich Ataxia.
P2860
Q24240370-A4D1ECD0-2BEE-4E09-B7D6-AD997C3E209EQ28488251-D39F8608-F3FB-4780-8BD5-45AACF63ED05Q30469947-FD319E2D-B9EC-484F-A968-0FB63365F6E0Q30581588-B2B09553-F210-4D74-B736-B4EDB4E31B25Q33634876-97EBAA0F-C726-419D-B67A-4E4E53C34899Q34197370-ADE20EF7-4D59-448B-9219-FB9773F652ECQ34666168-CF3BE5A3-6EB3-4404-9A67-C64A7189F4EFQ35737384-2B6FACC2-792E-4C56-B411-4BC641DF8991Q36010435-D8826AD5-0C03-469B-A926-5EFB2674AF55Q36517343-CF624FCA-35D1-4BE9-8063-778E04228E42Q36900827-B9494D68-D812-4DBA-A236-886D5C3C488FQ36907355-4C001D38-DD75-456D-A74A-F4ECEA4612D3Q37223281-41C05D3C-F514-49F8-8214-D31DAA905570Q37247066-7D4EF85F-2803-4C01-A7DB-5F9AA6D7ED91Q37631730-15A4C5AF-AA52-41F5-9D25-F3B78FB6C058Q37941519-27D50F3A-B39A-4BDA-A940-3B8E11683296Q38038592-A292AC7E-8501-41CD-8390-672211CCDFC7Q38121949-39C96FB0-7D21-4ED9-BEF4-0434C5BC72C4Q38219382-3008423B-5551-4C70-B9B7-906B8DC6CB6CQ38786942-C218A240-6106-4AB5-A855-D414A7669FE8Q39445743-6486AB9F-B4D0-4D11-819D-7CCAB2E3F447Q41509984-1AB6E9DA-F011-4211-9B90-2881C28561CCQ42686810-1B8E05FB-974B-42DB-8A13-CC72D5839EFDQ42731417-C2B7AC38-120F-455A-B063-7F727DBBC499Q42859119-7B7A9C3C-FD45-458A-A9A2-EA11ED682FD8Q42912971-284A7A9F-696E-46A5-9F6E-3F8033BF650DQ44940403-226A7693-0939-4490-A5EB-DDD2A8EBC5E0Q45809518-6A1D0309-8B98-4CB6-92EB-79B56F0D6459Q45868220-40CC2CBF-3ADC-4083-9BD3-8F71D08659A2Q46360528-812E01E3-42ED-4F21-B53F-3C51AFD429F9Q47786184-507BFDAE-1BC9-4B60-9784-045B2D4A10E7Q47927277-7EADDF99-93B9-461C-9B07-7C779CF53BC1Q48093411-F9AC0721-4F0C-4AC5-92F7-38175865847BQ48311885-72DD1DAD-3E6C-41D8-8E6E-C49ED24F2CF8Q48957646-5605D899-3950-4420-9FE1-70C5F75209E6Q50458074-B2455DBE-ABE6-4D24-B7B5-1924C438DEF5Q50536618-A5B1D519-AEAC-40CF-BEAC-DEAB69119FA6Q50887821-A4F633B3-117C-4A46-AD1F-920762F51DB0Q51076371-F488138D-56E3-488D-8609-35F7927B09EFQ51766578-55A593C8-67A8-493B-B06F-77379FE14107
P2860
Measuring Friedreich ataxia: complementary features of examination and performance measures.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Measuring Friedreich ataxia: c ...... tion and performance measures.
@en
Measuring Friedreich ataxia: c ...... tion and performance measures.
@nl
type
label
Measuring Friedreich ataxia: c ...... tion and performance measures.
@en
Measuring Friedreich ataxia: c ...... tion and performance measures.
@nl
prefLabel
Measuring Friedreich ataxia: c ...... tion and performance measures.
@en
Measuring Friedreich ataxia: c ...... tion and performance measures.
@nl
P2093
P1433
P1476
Measuring Friedreich ataxia: c ...... tion and performance measures.
@en
P2093
Ashizawa T
Subramony SH
P304
P356
10.1212/01.WNL.0000218155.46739.90
P407
P577
2006-06-01T00:00:00Z